INNOVATION ARTICLES
-
![Safety Equipment, Analyzing Sample Using Laboratory Equipment-GettyImages-2287737600]( "Years Before Clinical Trials: The Decisions That Shape The Future Of Academic Cancer Discoveries")
Years Before Clinical Trials: The Decisions That Shape The Future Of Academic Cancer DiscoveriesDavid Adler, MD, Ph.D., MBA, explains how earlier collaboration between academic and pharma researchers can strengthen oncology discoveries that lead to clinical trials.
-
![neurodegenerative diseases, parkinsons, alzheimers-GettyImages-2165648263]( "Targeting MSH3 To Slow Huntington's Disease Progression")
Targeting MSH3 To Slow Huntington's Disease ProgressionA study published in Nature Communications integrates a predictive computational model of Huntington’s disease built on human data, designed to reduce MSH3 expression in striatal and cortical neurons
-
![advances in science and technology-GettyImages-2184219775]( "How Peptides Are Expanding The Possibilities Of Drug Discovery")
How Peptides Are Expanding The Possibilities Of Drug DiscoveryGLP-1 therapies demonstrate the impact peptide medicines have. The opportunity ahead is to extend that impact across a much broader range of biology and achieve new ways to intervene.
-
![Industry Norm DDO San Diego]( "Built To Avoid Risk: How Industry Norms Stall Drug Discovery")
Built To Avoid Risk: How Industry Norms Stall Drug DiscoveryAt Discovery & Development US 2026 in San Diego, discovery leaders named the industry norms they would change.
-
![GettyImages-1449007950]( "Can CoRegen's Treg Platform Dismantle Solid Tumors' Immune Shield?")
Can CoRegen's Treg Platform Dismantle Solid Tumors' Immune Shield?Backed by $93 million, CoRegen is bringing a novel Treg-engineering strategy into the clinic to test whether CRG-150 can dismantle solid tumors’ immune defenses.
-
![GettyImages-2158228359]( "Discovery & Development US 2026 - Key Notes From San Diego")
Discovery & Development US 2026 - Key Notes From San DiegoKey takeaways from D&D US 2026 on Pfizer’s complex oncology targets, AI-enabled discovery, and the shift toward human-based NAMs.
INNOVATION VIDEOS
Achieve reliable, on-demand protein production with a manufacturing approach that minimizes scale-up risk from R&D through commercialization.
Explore how human-relevant liver models can improve DILI risk assessment and support stronger development decisions while advancing toward regulatory qualification and scaling into automated studies.
Discover how advanced ionizable LNP formulations and scalable manufacturing strategies can accelerate the development and clinical translation of personalized cancer vaccines.
Boost scalability in bioprocessing with automated filtration solutions designed for commercial-scale operations. Achieve reliable performance, low working volumes, and large filtration areas.
INNOVATION ARTICLES. APP NOTES, CASE STUDIES. & WHITE PAPERS
-
![GettyImages-153664932-scientist-pipette-gloves-assay]( "Building A Resilient Supply Chain For Complex IVD Reagents (Or Proteins)")
Explore how matching expression systems to diagnostic protein needs can improve yield, consistency, and scalability while reducing supply risks for IVD assays.
-
![GettyImages-1437856375-lnp-lipid-nanoparticle]( "From LNP Delivery To Functional CAR-T: Rethinking Targeting")
Optimizing LNPs for in vivo CAR-T requires aligning target selection, formulation design, and delivery performance to achieve functional CAR expression in desired T-cell populations while balancing specificity, safety, dosing flexibility, and manufacturability.
-
![Lipid Nanoparticles GettyImages-1437855772]( "Top 5 Things To Know About The Lipid Nanoparticle Portfolio")
Lipids that shift charge with pH can be chosen to fit the application and delivery route. Varied pKa and biodegradability give developers room to match each therapeutic target.
-
![nucleic acid, DNA, RNA, purified protein-GettyImages-1350828873]( "Expand mRNA-LNP Nanomedicine Potential By Optimizing Lipids")
Ionizable lipid selection ratios shape how well lipid nanoparticles deliver nucleic acids, and empirical testing shows that similar physical properties can still produce very different performance.
-
![GettyImages-2153976466-protein-3d-model-render]( "Why Protein Motion Matters As Much As Protein Structure")
Protein structures are not static. See how conformational changes influence physiological function and how electron paramagnetic resonance spectroscopy provides insights into effective design.
-
![GettyImages-2204734561]( "How Does EPR Spectroscopy Complement Cryo-EM?")
Discover how EPR complements structural maps by resolving flexible regions, detecting hidden conformational states, identifying differences between grid-based and solution conditions, and revealing the dynamic changes that connect molecular structure with biological function.
INNOVATION SOLUTIONS
-
![process control for monoclonal antibodies, recombinant proteins, probiotics, GLP-1 production-GettyImages-2281853896]( "Rescuing Proteins With Scalable Insect Expression")
Overcome protein expression bottlenecks with a scalable insect-based platform that delivers faster development, predictable scale-up, and consistent manufacturing.
-
![GettyImages-675822772-scientist-holding-book-with-bioreactor]( "The EntoEngine: Fruit Flies For Advanced Biomanufacturing")
Produce recombinant proteins at scale with stable expression, flexible batch sizes, and streamlined manufacturing.
-
![Why choose FATHOM]( "Quantum-Enabled EPR For Structural Biology And Drug Discovery")
Capturing dynamic conformational states is key to target druggability. Advanced EPR spectroscopy delivers nanometer-resolution measurements for complex structural biology.
-
![GettyImages-2184219775-chemistry-research-molecules]( "Designed For Difficult Biology")
Macrocycles expand drug discovery into previously inaccessible targets. With validated success and flexible approaches, they provide a powerful path for tackling the most challenging biology.
-
![drug-product-GettyImages-1293772880]( "Hybridoma Services")
Curia’s in vivo Discovery Immunology team offers high-performance hybridoma-based technologies to help clients discover great antibodies that make a difference.
-
![mAb, monoclonal antibody, antigen, vaccine-GettyImages-2245122166]( "Phage And Yeast Display")
Curia offers phage and eukaryotic-based yeast display platforms for in vitro discovery and engineering of potent antibody candidates for therapeutic or diagnostic use. High-affinity functional antibodies are routinely selected against a wide range of conventional or challenging targets (e.g. GPCRs) using customized or in-licensed state-of-the-art libraries.
-
![GettyImages-2151620900 antibody, IgG]( "Recombinant Antibody Production")
Curia has extensive experience with constructing and producing antibodies in our mammalian platforms.
-
![antibody molecules-GettyImages-2165626333]( "Antibody Developability Analysis")
Evaluating the developability of therapeutic drug candidates early can help circumvent potential issues in late-stage development.
-
![cmo-cdmo-drug-discovery-GettyImages-184944030 (1)]( "Small Molecule Discovery Network And Capabilities")
Our collaborative approach, proven track record, and deep technical expertise enable us to efficiently advance promising candidates, reduce development risk, and help transform innovative ideas into successful therapeutic realities.
-
![GettyImages-2189362114-recombinant-protein-structure]( "Protein Expression And Analysis")
Curia’s expert scientists use advanced technology to produce and analyze high-quality recombinant proteins.
-
![cmo-biologics-GettyImages-1327624070]( "Biologics Discovery")
Make the most of your molecule with integrated antibody discovery, engineering, and production capabilities designed to accelerate lead identification and optimization.
-
![GettyImages-2192786673 antibodies]( "Antibody Discovery And Engineering")
The Antibody Center at Curia provides end-to-end services in antibody discovery, engineering, and development.
-
![nano molecular structure-GettyImages-1350457469]( "Molecular Biology")
Our Biologics services provide comprehensive Molecular Biology services at facilities in California and Massachusetts, offering a variety of services.
-
![Protein ribbon structure-GettyImages-2192885402]( "Recombinant Protein Production")
Curia has decades of experience in recombinant protein production.
